Abstract
Dementia is an eurodegenerative disorder, which causes significant disability, especially among the elderly population worldwide. The affected person shows a progressive cognitive decline, which interferes with the independence in performing the activities of daily living. Other than the cognitive domain, the patient tends to have neuropsychiatric, behavioral, sensorimotor, speech, and language-related issues. It is expected that the global burden of the disease will rise with more people entering the geriatric age group. By 2050 close, to 140 million people will be living with one or the other type of dementia. Alzheimer’s disease contributes to more than 60% of cases worldwide, followed by vascular dementia.
Pharmacotherapy has a limited role to play in the treatment, and at present, no drug is available, which can halt or reverse the progress of the disease. World Health Organization has mandated rehabilitation as a core recommendation in the global action plan on the public health response to dementia. Rehabilitation services are widely recognized as a practical framework to maximize independence and community participation in dementia care. The rehabilitation program is customized to achieve the desired goals, as each person has different experiences, preferences, motivations, strengths, and requirements based on type, course, and severity of the illness. It is an interdisciplinary-team approach with the involvement of several health care professionals. This article reviews the existing literature and outlines the effective rehabilitation strategies concisely in dementia care.
Keywords: Dementia, geriatric psychiatry, rehabilitation, review
Dementia is a global public health concern and a significant cause of disability among the elderly population worldwide.1 It is a neurodegenerative disorder characterized by a significant cognitive decline that interferes with independence in activities of daily living (ADL).2 In 2015, about 46 million people lived with dementia globally, and this number is expected to triple by 2050, with two-third population residing in low or middle-income countries.3 In India, the prevalence of dementia is about 2.7% among people aged above 60 years.4–7 The increasing disease burden globally will command a mammoth socioeconomic hardship in countries worldwide with far more complicating circumstances in low-income countries.6,8
Alzheimer’s disease (AD) contributes to 60% of the cases of dementia followed by vascular dementia.9 Frontotemporal dementia (FTD) is almost equivalent to AD among patients younger than 65 years age group.10 Parkinson’s disease (PD) dementia and dementia with Lewy bodies (DLW) are the other rare causes of dementia.11,12
AD most frequently presents with early impairment in episodic memory, with deficits in other cognitive domains, such as semantic memory, language, executive function, and visuospatial abilities.13 In vascular dementia, executive functioning, attention, and perception are more affected than episodic memory.14,15 Parkinsonian dementias are distinguished by impairment in attention and executive function.16 Among the FTDs, the behavioral variant presents with early changes in behavior, personality, and executive dysfunction, while the semantic variant is characterized by naming deficits and loss of conceptual knowledge.17,18
A comprehensive rehabilitation program plays a major role in pharmacotherapy in the management of people living with dementia. Hence, it is necessary to have proper guidelines for the rehabilitation of these patients. This article reviews the existing literature related to management strategies and outlines the effective multidisciplinary rehabilitation program concisely in dementia care.
A Comprehensive Approach to Rehabilitation in Dementia
World Health Organization mandated rehabilitation as a core recommendation in the global action plan on the public health response to dementia. Rehabilitation services are widely recognized as a practical framework to maximize independence and community participation in dementia care.19,20 A rehabilitation program is customized to achieve the desired goals, acknowledging that each person with dementia has a unique experience, preference, motivation, strength, and requirement.19 It is an interdisciplinary-team approach with the involvement of several health care professionals. The clinician heading the team could be a neurologist/psychiatrist. In a rehabilitation department, it is headed by a physiatrist/rehabilitation physician. Other members comprise psychologists, physiotherapists, orthotist, occupational therapists, speech and language therapists, social workers, etc.
Clinical Assessment and Relevant Pharmacotherapy
People with dementia have symptoms in many domains, including cognition, neuropsychiatric symptoms, behavior, and ADL, in addition to comorbid illnesses. The rehabilitation team has to consider a person’s needs in a holistic way to address medical, cognitive, behavioral, physical, and social issues.21 Thus, a comprehensive clinical assessment is required to design a customized program.
More often than not, dementia is associated with comorbid medical illnesses, which may be confused for the symptoms of dementia. Timely identification and management of the comorbidities are crucial for better functioning and the global well-being of the individual.22 Common comorbidities that are likely to require medical attention are diabetes, hypertension, heart failure, anemia, cardiac arrhythmia, pressure ulcers, osteoporosis, and thyroid disease.23 Unnecessary exposure to sedative-hypnotics and anticholinergic medications hurt cognition among older people.24,25 Hence, medication review is invariably appropriate to minimize polypharmacy.
Sensory-Motor Rehabilitation
Gait Disorders
Gait deviation, balance, and motor impairments are common in people with dementia and are associated with an increased risk of falls.26–28 There are diverse patterns of gait deviations reported across subtypes of dementia, and in general, they are more prominent in Lewy Body Dementia (LBD) and PD as compared to AD.27,29 But some studies have reported gait dysfunction in the early stage of AD.30,31 The gait and motor impairment patterns vary with the disease severity and may include gait apraxia, bradykinesia, extrapyramidal rigidity, resting tremor, and various other gait disorders.27,31–33 The most prevalent impairment reported is a cautious gait in mild AD, which is nonspecific and could be related to other conditions such as arthritis, peripheral sensory, and motor neuropathy. Frontal gait disorder, characterized by striking disequilibrium, short steps, shuffling, and hesitation, may be observed in moderate and severe AD.34 Poor cognition in these patients is associated with slower walking speed.35 Simultaneous cognitive task (dual tasking) also leads to gait dysfunction in early dementia. Temporal disturbances (slower speed), spatial disturbances (variable step length and step width), and instability in single stance (balance impairment) are the different gait dysfunctional patterns, which have been reported during dual-tasking.36
Gait Rehabilitation
Gait training focusing on the ADL such as sit to stand from a chair, kneeling, walking, turning are useful in improving mobility and are considered better than resistance and flexibility exercises. Concomitant cognitive intervention along with walking may aid in improving gait.37 As the individual shows improvement, the challenge of the task can be increased to better the gait speed and coordination of walking.38 Other strategies like rhythmic music have been reported to show improvement in the walking speed in individuals with AD.39
Falls
Evidence suggests that older adults with AD, even at an early stage, are at greater risk of falls than their age-matched peers without dementia.26,35,40 The increased risk can be explained by the interaction of various risk factors such as physiological changes (visual impairment, osteoporosis), autonomic symptoms, physical inactivity, sensory neuropathy (associated with diabetes), orthostatic hypotension, and polypharmacy. Postural control is mediated by integrating sensory, motor, visual, cognitive, and vestibular networks. Any disruption in the circuit can lead to postural instability, a major factor in falls in people with dementia.41,42 Community-dwelling people with dementia are at higher risk of hip fracture secondary to a fall.43
Fall Prevention Strategies
Exercise intervention focusing on improving gait, balance, and strength effectively reduces fall and fall-related fractures in the older population.44 An exercise program of mild to moderate intensity, practiced twice a week and focusing on balance, will help in preventing falls.45 Fall prevention strategies need to be individually tailored considering the felt need of the patients and their caregivers and should include home safety modifications.46 There is limited evidence regarding the effectiveness of conventional strategies in people living with dementia across hospital setup, residential care, and community.47,48 A recent Cochrane review showed insufficient evidence for effective rehabilitation following hip fracture in people living with dementia.49
Physical Exercise and Lifestyle
Regular physical exercise is recommended to all older adults, as it may improve physical health, reduce frailty, decrease the risk of depression, and improve cognitive function.50,51 A minimum of 150 minutes of moderate exercise is recommended every week for health benefits.52 However, 30 minutes of physical exercise three times a week may improve cognition in people with dementia.53
Regular physical activity may lessen the risk of AD and slow the onset or progression.53–55 A prospective study on women observed that physical and cognitive exercises at midlife reduce the risk of AD and dementia occurring later in life.56 Physical activity of moderate intensity may be associated with a reduced risk of developing dementia in people with mild cognitive impairment.57
A recent multicentric study in the UK (DAPA Trial) did not show any positive effect of moderate to high-intensity exercise on cognition.58 A Cochrane review endorsed the positive effect of exercise programs in preserving independence in ADL in persons with dementia but showed poor evidence of benefit on cognition and neuropsychiatric symptoms.59 Still, this finding is of some significance because maintaining functional independence is crucial for enhancing the quality of life of persons with dementia and their caregivers and for preventing hospitalization.
There is wide heterogeneity in the individual response to physical exercise, especially in strength and endurance programs.60 Genetic factors and diet and exercise regime (volume, duration, frequency, type of exercise) may contribute to exercise insensitivity in some of these persons with dementia.61
High-volume physical exercise may help to overcome the lack of training effect.62 However, the effective dose of exercise and its response to cognition is still not well understood. Brain-derived neurotrophic factor (BDNF) is a potential mediator of exercise-induced neuronal plasticity that may improve cognition.63–65 The exercise interventions should be exhaustive enough to build lactate levels. Higher lactate concentrations are correlated with raised BDNF levels.66,67 High-Intensity Interval Training (HIIT) could be a method to gain larger BDNF levels. There is increasing evidence about the beneficial effects of HIIT training for older populations with chronic diseases such as chronic heart failure and chronic obstructive pulmonary disease.68 Majority of exercise programs studied in dementia incorporated moderate to high-intensity exercise, not HIIT.57,58 Though further research is awaited, HIIT can be a worthwhile exercise regime for preventing cognitive decline in persons with dementia.69
The exercise regime investigated in dementia care includes various training programs such as aerobic exercise, resistance training, balance, and flexibility training. Further studies are required to determine the minimum duration, type, and intensity of exercise required to improve cognitive function in dementia. A personalized exercise program should be prescribed depending on performance analysis and modifiable individual factors.70
Some of the large randomized controlled trials (MAPT, PreDIVA, and FINGER) looked at the effect of multidomain lifestyle interventions on cognitive functions and prevention of dementia.71–73 Beneficial effects of diet and physical exercise on cognitive functions among people at risk of dementia have been reported in the FINGER trial.73
Cognition
Dementia is characterized by a significant cognitive decline in one or more cognitive domains leading to the inability to perform everyday activities and participate in social life. As a result, cognitive impairments have a tremendous impact on patients’ quality of life and their caregivers.
Cognitive rehabilitation (CR) is a common nonpharmacological approach to address cognitive issues in people living with dementia. There are three main strategies proposed for intervention. These include, cognitive stimulation (CS), cognitive training (CT), and CR.74
Cognitive Stimulation
CS is a nonspecific approach to stimulate all cognitive domains. A wide range of activities such as reminiscence therapy, reality orientation, and sensorimotor therapy has been tried in individual and group formats and have shown social functioning and global cognition benefits. CS has the most reliable evidence among cognitive interventions. Several studies have described a positive effect of CS on the enhancement of overall cognitive functioning in mild-to-moderate dementia.75–77 A current systematic review revealed the beneficial effect of CS on the Mini-Mental State Examination.78
Cognitive Training
CT conventionally involves the repeated practice of a set of structured tasks intended to improve or maintain a particular cognitive function. The central theory underlying CT is that repeated training can enhance or maintain a concerned cognitive function. The practice also helps to perform better in a related but different task based on the same cognitive ability. CT may be delivered individually or in a group session. Computerized CT has largely replaced the conventional “paper and pencil” format. In CT, the target task is divided into small elements to improve underlying cognitive processes, and repeated performance leads to neuroplasticity in the brain.79–81
CT has shown promising results in older adults and people with minimal cognitive impairment with level C evidence.82–85 In contrast, the evidence of CT in patients with moderate and severe dementia is poor with questionable effects on global cognition and verbal semantic fluency.81,83,86
Cognitive Rehabilitation
CR is a person-centered intervention that addresses the impact of cognitive dysfunction on everyday activities and enables the person to execute the desired action.87 In CR, rehabilitation therapist engages both patient and caregivers to determine realistic goals associated with day-to-day activities based on a person’s functioning and cognitive demand of the desired goal. CR guides the person with dementia to achieve the desired goal using evidence-based rehabilitation techniques. These techniques may comprise environmental modifications, compensatory strategies, memory aids, and procedural learning of skills. A rehabilitation plan is put into practice in the home setting to make realistic situations.87,88 A multicentric randomized trial (The GRAET trial) confirms positive evidence of an individualized CR to improve daily life in people with early-stage dementia.89
Behavioral and Psychological Symptoms of Dementia
In addition to cognitive decline, people with dementia suffer from several neuropsychiatric symptoms, collectively called behavioral and psychological symptoms of dementia (BPSDs). It includes disorder of perception (delusion, hallucination), aberrant motor behavior (wandering, repetitive movements, aggression), emotional issues (apathy, depression, anxiety, irritability, euphoria, disinhibition), and vegetative symptoms (sleep or appetite changes).90,91 Majority of people with dementia experience BPSD in the community as well as in in-hospital setup. The most common neuropsychiatric symptoms in community-dwelling patients are delusions, agitation, motor hyperactivity, and apathy. In contrast, aggression, irritability, night-time restlessness, unusual motor behavior, and disinhibition are frequently reported in hospitalized patients.91,92 In the Indian population, the highest prevalence of BPSD is in FTD, followed by DLB, and the least in vascular dementia.93 It is important to evaluate BPSD at an early stage to avoid rapid progression in AD.94
The etiology of BPSD is multifactorial. It is probably the effect of a complex interaction of psychological, social, and biological factors. Neuroimaging shows reduced metabolism and volume reduction in the prefrontal cortex, anterior cingulate, and temporal lobe, associated with certain BPSD symptoms like apathy and psychosis.95 The determinants of BPSD include various factors such as premorbid personality, genetics, coexisting medical conditions, drugs, and unmet physical needs. Environmental factors such as crowding, noise, isolation, inadequate temperature, change of schedule, as well as the inappropriate interaction between patient and caregiver or the inadequacy of the patient to communicate his requirements, may all precipitate BPSD.96
Management of BPSD
A thorough history and physical examination of the patient and caregivers is necessary to come to an individualized treatment plan. Acute or subacute onset of symptoms should be promptly investigated (e.g. infection, dyselectrolytemia, substance intoxication) to rule out causes of delirium, which usually need hospitalization. Assessing the severity of symptoms is the priority, especially for patients who are endangering the life of themselves or others who will need aggressive management.97 More than half of the persons with dementia suffer from daily pain, which may precipitate depression, agitation, and aggression.98
Since neuropsychiatric symptoms can fluctuate and their assessment is subjective, establishing a clear baseline for evaluating the effects of treatment is important. Neuropsychiatric inventory (NPI) or the behavioral pathology in AD rating scale (BEHAVE-AD) is the standardized tool based on caregiver’s interview and used commonly for overall BPSD assessment.99,100
Nonpharmacological Interventions
Currently, NPI is considered the first-line treatment for the management of BPSD.101,102 The nonpharmacologic methods underlying the DICE approach (Description of the problem, Investigation for the cause, Create a treatment plan, Evaluate the Effectiveness) has substantial evidence, including detailed assessments of underlying causes and caregiver interventions.103
NPI can be delivered by targeting the patients, caregivers, and the environment.103 The intervention extends from sensory stimulation to cognitive and behavioral approaches. Sensory stimulation includes aromatherapy, massage, music/dance therapy, light therapy, snoezelen therapy, and TENS therapy. Cognition-oriented interventions incorporate reminiscence therapy, validation therapy, and simulated presence therapy.
All these nonpharmacological interventions confer potential benefits; however, the strength of evidence is overall insufficient. Music-based intervention is effective in reducing depressive symptoms and anxiety, and improve the overall quality of life.104 Massage therapy may positively affect behavioral and psychological symptoms; however, more research is warranted.105,106 Aromatherapy, light therapy, and TENS have limited benefits for people with dementia.107,108 The evidence to support cognitive/emotion-oriented interventions, which include validation therapy, simulated presence therapy, and reminiscence therapy, is lacking.109,110
Patients with higher cognitive functioning, fewer obstacles to perform ADL, communication, and speech may better respond to these interventions. Staff barriers and the presence of pain are associated with a poor outcome.111 Nonpharmacological interventions need to be tailored, and they should be chosen considering the possible causes of a patient’s behavioral and psychological symptoms.112
Psychological Therapy
There is evidence that structured psychological interventions combined with routine care can decrease symptoms of depression and anxiety in dementia. They improve patients’ psychological well-being, while no impact was observed on everyday activities and quality of life.113 Short-term group therapy immediately after diagnosis of dementia aids in improving symptoms of depression and quality of life, while personalized and multicomponent therapy appears to reduce improper behavior in people with a mild-to-moderate grade of impairment.114
Pharmacotherapy
Antidepressants: Antidepressants are preferred for the management of BPSD due to their low side effect but with limited evidence. They are more effective for managing agitation compared to depression, anxiety, or psychosis.115
In 2014, the CitAD trial showed promising evidence for the efficacy of Citalopram in reducing agitation, improving ADL performance, and caregiver stress in patients with AD. However, Citalopram had a risk of QT prolongation, limiting its wide use.116 Although, Sertraline has a good cardiac safety profile, evidence for its efficacy is mixed. Antidepressants with anticholinergic properties like paroxetine and tricyclic antidepressants should usually be avoided.115 Though low dose of Trazodone at 50 mg may not be effective in improving sleep and 150–300 mg daily dose was found useful in diminishing some behavioral symptoms in FTD.117,118 Mirtazapine didn’t show any positive effect in sleep disorder in AD and rather worsened daytime sleep patterns.119
Antipsychotics: Antipsychotics have reasonable efficacy in treating agitation, psychosis, and aggression in persons with dementia. However, due to the adverse effect profile, their use is reserved for severe symptoms refractory to nonpharmacological interventions.120 Atypical antipsychotics are more effective for treating BPSD as compared to typical antipsychotics.121 Risperidone, Aripiprazole, Olanzapine, Haloperidol are the most common antipsychotics used in BPSD. American Psychiatric Association recommended that antipsychotics should be started at a low dose to be optimized up to the minimum effective dose as tolerated. Antipsychotics should be tapered and withdrawn after four weeks of adequate dose if there is no clinical response. In patients showing response to antipsychotics, medications should be tapered after four months of starting, except the patient encountered a recurrence of symptoms. A recent Cochrane review concluded that discontinuation of antipsychotics after three months of treatment is not associated with worsening BPSD or quality of life except in patients with more severe BPSD at baseline.122 Antipsychotic medications should be avoided in patients with Lewy body disease due to the high risk of extrapyramidal symptoms; instead, cognitive enhancer like donepezil can be used to treat BPSD in patients with LBD.123
Pimavanserin is recently approved for treating PD psychosis with modest efficacy. However, there is a concern for QT prolongation, drug interactions, increased mortality risk, and exorbitant cost.124 Pimavanserin showed a benefit for psychosis in AD at six weeks without any cognitive decline, but not after 12 weeks.125 Brexpiprazole (2 mg per day) is found to reduce agitation compared to placebo in patients with AD in a recent randomized controlled trial.126
Benzodiazepines: Benzodiazepines are widely used in dementia; however, evidence for efficacy is inadequate with the risk of side effects.120 Lorazepam can be used in extreme agitation or aggression, which is not manageable by other interventions.127 Clonazepam can help in REM behavior disorder.128
Pharmacotherapy may work as an adjunct to rehabilitation programs to enhance patient compliance and help them become more independent in daily living activities.
Bladder Involvement and Lower Urinary Tract Dysfunction (LUTD)
LUTD is a distressing condition in persons with dementia and is associated with ADL impairment and poor quality of life.129 LUTD refers to problems of either urinary storage or voiding. Storage symptoms include urinary urgency, frequency, nocturia, and urinary incontinence (UI), whereas voiding symptoms include hesitancy, poor flow, straining, a sensation of incomplete voiding, and urinary retention. The type of lower urinary tract symptoms is determined by the lesion distribution in the neural pathway.130
UI is the most prevalent complaint among storage symptoms in advanced dementia. In addition to cognitive and behavioral problems, urological problems such as detrusor overactivity can lead to UI in persons with dementia.131
Functional incontinence is UI that is not related to lower urinary tract pathology or micturition mechanism but occurs due to the inability to reach the toilet in time due to an impaired cognitive activity or mobility issues. People with vascular dementia, DLB, and FTD experience UI relatively at an early stage compared to AD and PD with dementia.131,132
A detailed history regarding the LUT symptoms, patient fluid intake, voiding complaints, and medications with anticholinergic effects should be considered. Maintaining a bladder diary that notes the time and volume of fluid intake and each voiding episode along with incontinence is essential as it provides a real-time, objective assessment of urinary symptoms. Peri-anal sensation, anal sphincter tone, bulbocavernosus reflex should be tested along with local abdomen and pelvis examination. Urinalysis is required to rule out urinary tract infections. Ultrasonography should be undertaken to check for pressure-related changes in the upper urinary tract (like hydronephrosis), bladder calculi, and significant post-void residual (PVR) urine. Raised PVR indicates voiding dysfunction. It could be due to acontractile detrusor or bladder outlet obstruction, for which urodynamics study would be required.131
Management
The management of LUTD is individually tailored according to disease status, the pattern of bladder dysfunction, and patient expectation, counting other factors such as cognitive impairment, mobility issues, and general health conditions.133 Among the nonpharmacological management strategies, behavioral therapy is considered to be the first-line treatment. If it is not successful alone, pharmacological therapy can be combined.
Behavioral Therapy
Behavioral therapy programs include prompted voiding, timed voiding, and pelvic floor muscles training (PMFT) to alleviate UI.
Prompted voiding: It can be tried as per the predetermined schedule in patients with cognitive impairment. The caregiver may enquire at regular intervals (two hourly during daytime) and provide support during toileting.129,134,135 Patients with low motivation and mobility issues can be trained for prompted and scheduled toileting.133
Timed voiding: Timed voiding is practiced by patients themselves, in which they follow a planned schedule to empty the bladder to prevent UI. Timed voiding is preferably used for patients with relatively intact cognition with neurogenic bladder.129
PFMT: Voluntary contraction of pelvic floor muscles causes activation of an inhibitory reflex on detrusor muscles and increases urethral pressure.136 Commonly, patients tend to contract rectus abdominis or glutei, rather than the pelvic floor muscles. Hence, it’s important to teach PFMT properly. By and large, the anus is contracted first as if raising the anus from the ground, and the pelvic muscles are contracted and relaxed alternatingly.129 Supervised PFMT is an effective approach to prevent UI in the elderly with mild cognitive impairment.137 It can be combined with auditory or visual biofeedback by recording biological signals (EMG activity) from the pelvic floor muscles to improve the therapeutic effect.138
Pharmacological Management
Antimuscarinic agents: Antimuscarinic agents suppress detrusor contraction through antagonism to muscarinic rece-ptors and improve urgency and urge incontinence.139 Oxybutynin, tolterodine, trospium are nonselective antimuscarinics as they act on all muscarinic receptors (M1–M5), while darifenacin and soli-fenacin are selective antimuscarinics with affinity to M2/M3 receptors located in the bladder. These anticholinergic medications have to be used cautiously in persons with dementia for obvious reasons as their mechanism of action affects memory adversely.
Mirabegron: Mirabegron, a beta-3 receptor agonist, activates the beta-3 receptors in the detrusor muscle, leading to relaxation of the bladder and improve bladder capacity.140 A recent clinical trial (PILLAR) reported no adverse impact on cognition following treatment with Mirabegron over 12 weeks.141
Other than behavioral and pharmacological treatment for bladder dysfunction, supportive measures like the use of adult diapers, external sheath drainage in males, especially during the night, intermittent catheterization can be effectively used for bladder management. Some cases may require surgical intervention like patients with prostatomegaly, augmentation cystoplasty, etc.
Inappropriate Sexual Behavior in Dementia
Inappropriate sexual behavior (ISB) is a relatively common troublesome behavior in people living with dementia.142 It causes significant distress for family caregivers attributing to the decision of institutionalization of a patient in selected cases.143 ISB has been estimated to be present in 7%–25% of dementia patients, and its prevalence is more in nursing facilities and in a patient with severe cognitive impairment. Inappropriate sexual talk is the most commonly reported behavior, almost 60% of all ISB. It is strongly associated with the presence of BPSD.142,144 People with vascular dementia tend to have more ISB.145 Moreover, hyposexual behavior and apathy towards the partner are mostly reported compared to aberrant or ISB among people with FTD.146
Management of Inappropriate Sexual Behavior
It becomes an important issue to be addressed by the rehabilitation team if patients are showing ISB.
Existing literature provides several nonpharmacological and pharmacological approaches to treat dementia-related ISB; evidence regarding their efficacy is insufficient due to limited research in this area.142,145,147
Nonpharmacological Management
Nonpharmacological methods are the first-line treatment, and it should be an individualized approach involving family and caregivers. Common examples include the elimination of aggravating factors, distraction tactics, and chances to relieve sexual urges.
Pharmacological Management
Pharmacological treatments should be prescribed only when the conservative approach fails to relieve the symptoms. In addition, it is necessary to explain the possible benefits and risks of the drugs to the patients or family members, as all the medications can only be used off-label. Pharmacological treatments used to treat ISB include antidepressants, antipsychotics, anticonvulsants, cholinesterase inhibitors, hormonal agents, and beta-blockers.
Activities of Daily Living in Dementia
A decline in the performance of ADL is a defining characteristic of dementia. ADL consists of basic ADL (BADL) such as eating, grooming, bathing, dressing, and toileting, and instrumental ADL (IADL) such as cooking meals, doing household chores, shopping, handling finances and other more complex skills. BADL is affected in moderate to severe ADL stages, whereas impairment in IADL is detected in mild cognitive impairment and early stages of dementia.148 Cognitive decline is strongly correlated with the inability to perform ADL and poor functional status.149 Executive cognitive dysfunction is likely to undermine the ability to carry out complex IADL as well as BADL. Behavioral symptoms, especially apathy, is significantly associated with impairments in functional abilities.150
Multimodal occupational therapy intervention uses a consolidated strategy that includes task simplification, environmental adjustment, adaptive devices, and caregiver education to improve functional abilities and performance in ADL.151,152 Therapists involve the caregiver during the session to identify the desired goals, tailor the activities for the person with dementia, and mitigate the environmental barriers to maintain their interest and participation. There is substantial evidence that home-based occupational therapy improves ADL performance as well as the quality of life.153
An evidence-based review proposed that patient-tailored and activity-based leisure intervention may enhance caregiver satisfaction. In contrast, interventions targeted on ADL and IADL may improve the well-being and quality of life of people living with dementia. Social participation and communication, primarily involving people in the early or middle stage of dementia when verbal abilities are spared, found to have a short-term positive effect on the patient’s well-being.154
Assistive Technology and Devices in Dementia Care
Assistive technology can play an important role in dementia care. It has the potential to ease ADL tasks, build confidence and safety, and reduce neuropsychiatric symptoms, and thus helps to improve the quality of life of people living with dementia and their caregivers.155
Simple assistive devices include walking sticks, standard and wheeled walkers, manual wheelchairs, and motorized wheelchairs and these are often prescribed to people with dementia. Walking using a cane or wheeled walker demands cognitive abilities, leading to a decrease in walking speed in mild to moderate dementia.156,157 Assistive devices for daily living can be used to improve memory, communication difficulties, and orientation. Prospective memory aids consisting of digital display of calendar, voice reminder device for keeping daily appointments, medication schedule, etc.158
Targeted use of assistive technology can improve safety and reduce distress in caregivers. These devices include automated shut-off devices that can stop the gas supply after use, sensor lights, automatic water taps that can prevent wastage of water, and or fall sensors that can record if a person has sustained a fall. Besides, these safety devices also include tracking technologies based on a global positioning system that detect the individuals’ location if they were to get lost.159 Social interaction with friends and family has a positive impact on cognition and well-being. Technology facilitated games can stimulate communication and social behavior.160 Assistive devices focus on improving the quality of life and should be prescribed considering the patient’s needs and privacy.161
Most of the rehabilitation strategies discussed in this article have got a global application and hence can be useful irrespective of the geographic location. The use of local and affordable material and technology has to be prioritized to get cost-effective and optimum gain out of rehabilitation programs in dementia care.
In India, the concept of multidisciplinary rehabilitation is confined to very few higher education teaching institutes or hospitals in big cities. Therefore, the horizontal spread of these services in tier-2 cities and towns, and awareness about rehabilitation among the public and other medical/health professionals would be the initial step to improve dementia care in the country.
Footnotes
Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
- 1.Nichols E, Szoeke CEI, Vollset SE, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol January 2019; 18(1): 88–106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th ed. American Psychiatric Association Publishing, 2013. [Google Scholar]
- 3.Prince M, Wimo A, Guerchet M, et al. World Alzheimer Report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International, 2015. [Google Scholar]
- 4.Chandra V, Pandav R, Dodge HH, et al. Incidence of Alzheimer’s disease in a rural community in India: The Indo-US study. Neurology September 2001; 57(6): 985–989. [DOI] [PubMed] [Google Scholar]
- 5.Das SK, Biswas A, Roy T, et al. A random sample survey for prevalence of major neurological disorders in Kolkata. Indian J Med Res August 2006; 124(2): 163–172. [PubMed] [Google Scholar]
- 6.Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol September 2008; 7(9): 812–826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Shaji S, Bose S, and Verghese A. Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry February 2005; 186(2): 136–140. [DOI] [PubMed] [Google Scholar]
- 8.Das SK, Pal S, and Ghosal MK. Dementia: Indian scenario. Neurol India December 2012; 60(6): 618–624. [DOI] [PubMed] [Google Scholar]
- 9.Qiu C, Kivipelto M, and von Strauss E. Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci June 2009; 11(2): 111–128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Harvey RJ, Skelton-Robinson M, and Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry September 2003; 74(9): 1206–1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kushwaha S, Talwar P, Anthony A, et al. Clinical spectrum, risk factors, and behavioral abnormalities among dementia subtypes in a North Indian population: A hospital-based study. Dement Geriatr Cogn Disord Extra August 2017; 7(2): 257–273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Stevens T, Livingston G, Kitchen G, et al. Islington study of dementia subtypes in the community. Br J Psychiatry March 2002; 180(3): 270–276. [DOI] [PubMed] [Google Scholar]
- 13.Weintraub S, Wicklund AH, and Salmon DP. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med April 2012; 2(4): a006171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Looi JC and Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology, 1999. September 11; 53(4): 670–678. [DOI] [PubMed] [Google Scholar]
- 15.Villardita C. Alzheimer’s disease compared with cerebrovascular dementia. Neuropsychological similarities and differences. Acta Neurol Scand April 1993; 87(4): 299–308. [DOI] [PubMed] [Google Scholar]
- 16.Kudlicka A, Clare L, and Hindle JV. Executive functions in Parkinson’s disease: Systematic review and meta-analysis. Mov Disord November 2011; 26(13): 2305–2315. [DOI] [PubMed] [Google Scholar]
- 17.Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain September 2011; 134(9): 2456–2477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Snowden J, Goulding PJ, and David N. Semantic dementia: A form of circumscribed cerebral atrophy. Behav Neurol January 1989; 2(3): 167–182. [Google Scholar]
- 19.Clare L. Rehabilitation for people living with dementia: A practical framework of positive support. PLoS Med March 2017; 14(3): e1002245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Ravn MB, Petersen KS, and Thuesen J. Rehabilitation for people living with dementia: A scoping review of processes and outcomes. J Aging Res June 2019; 2 1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Tanner JA, Black BS, Johnston D, et al. A randomized controlled trial of a community-based dementia care coordination intervention: Effects of MIND at Home on caregiver outcomes. Am J Geriatr Psychiatry April 2015; 23(4): 391–402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Subramaniam H. Co-morbidities in dementia: Time to focus more on assessing and managing comorbidities. Age Ageing May 2019; 48(3): 314–315. [DOI] [PubMed] [Google Scholar]
- 23.Bunn F, Burn A-M, Goodman C, et al. Comorbidity and dementia: A scoping review of the literature. BMC Med October 2014; 12(1): 192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: A nested case-control study. JAMA Intern Med June 2019; 179(8): 1084–1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Lee J, Jung SJ, Choi J-W, et al. Use of sedative-hypnotics and the risk of Alzheimer’s dementia: A retrospective cohort study. PLoS One September 2018; 13(10): e0206094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Allali G and Verghese J. Management of gait changes and fall risk in MCI and dementia. Curr Treat Options Neurol July 2017; 19(9): 29. [DOI] [PubMed] [Google Scholar]
- 27.McArdle R, Galna B, Donaghy P, et al. Do Alzheimer’s and Lewy body disease have discrete pathological signatures of gait? Alzheimers Dement October 2019; 15(10): 1367–1377. [DOI] [PubMed] [Google Scholar]
- 28.Taylor ME, Delbaere K, Mikolaizak AS, et al. Gait parameter risk factors for falls under simple and dual task conditions in cognitively impaired older people. Gait Posture January 2013; 37(1): 126–130. [DOI] [PubMed] [Google Scholar]
- 29.Fritz NE, Kegelmeyer DA, Kloos AD, et al. Motor performance differentiates individuals with Lewy body dementia, Parkinson’s and Alzheimer’s disease. Gait Posture October 2016; 50 1–7. [DOI] [PubMed] [Google Scholar]
- 30.Gras LZ, Kanaan SF, McDowd JM, et al. Balance and gait of adults with very mild Alzheimer disease. J Geriatr Phys Ther March 2015; 38(1): 1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Waite LM, Grayson DA, Piguet O, et al. Gait slowing as a predictor of incident dementia: 6-year longitudinal data from the Sydney Older Persons Study. J Neurol Sci. March 2005; 229–230: 89–93. [DOI] [PubMed] [Google Scholar]
- 32.Camicioli R, Howieson D, Oken B, et al. Motor slowing precedes cognitive impairment in the oldest old. Neurology May 1998; 50(5): 1496–1498. [DOI] [PubMed] [Google Scholar]
- 33.Scarmeas N, Albert M, Brandt J, et al. Motor signs predict poor outcomes in Alzheimer disease. Neurology May 2005; 64(10): 1696–1703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.O’Keeffe ST, Kazeem H, Philpott RM, et al. Gait disturbance in Alzheimer’s disease: A clinical study. Age Ageing July 1996; 25(4):313–316. [DOI] [PubMed] [Google Scholar]
- 35.Dyer AH, Lawlor B, Kennelly SP, NILVAD Study Group. Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: Data from NILVAD. BMC Geriatr March 2020; 20(1): 117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Cedervall Y, Halvorsen K, and Aberg AC. A longitudinal study of gait function and characteristics of gait disturbance in individuals with Alzheimer’s disease. Gait Posture April 2014; 39(4): 1022–1027. [DOI] [PubMed] [Google Scholar]
- 37.Zhang W, Low L-F, Gwynn JD, et al. Interventions to improve gait in older adults with cognitive impairment: A systematic review. J Am Geriatr Soc February 2019; 67(2): 381–391. [DOI] [PubMed] [Google Scholar]
- 38.Schwenk M, Zieschang T, Englert S, et al. Improvements in gait characteristics after intensive resistance and functional training in people with dementia: A randomised controlled trial. BMC Geriatr, 2014. June; 14: 73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wittwer JE, Winbolt M, and Morris ME. Home-based gait training using rhythmic auditory cues in Alzheimer’s disease: Feasibility and outcomes. Front Med January 2020; 6: 335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Taylor ME, Delbaere K, Lord SR, et al. Neuropsychological, physical, and functional mobility measures associated with falls in cognitively impaired older adults. J Gerontol A Biol Sci Med Sci August 2014; 69(8): 987–995. [DOI] [PubMed] [Google Scholar]
- 41.Härlein J, Dassen T, Halfens RJG, et al. Fall risk factors in older people with dementia or cognitive impairment: A systematic review. J Adv Nurs May 2009; 65(5): 922–933. [DOI] [PubMed] [Google Scholar]
- 42.Morris JC, Rubin EH, Morris EJ, et al. Senile dementia of the Alzheimer’s type: An important risk factor for serious falls. J Gerontol July 1987; 42(4): 412–417. [DOI] [PubMed] [Google Scholar]
- 43.Hsu B, Bleicher K, Waite LM, et al. Community-dwelling older men with dementia are at high risk of hip fracture, but not any other fracture: The Concord Health and Aging in Men Project. Geriatr Gerontol Int October 2018; 18(10): 1479–1484. [DOI] [PubMed] [Google Scholar]
- 44.Guirguis-Blake JM, Michael YL, Perdue LA, et al. Interventions to prevent falls in older adults: Updated evidence report and systematic review for the US preventive services task force. JAMA April 2018; 319(16): 1705–1716. [DOI] [PubMed] [Google Scholar]
- 45.Sherrington C, Whitney JC, Lord SR, et al. Effective exercise for the prevention of falls: A systematic review and meta-analysis. J Am Geriatr Soc December 2008; 56(12): 2234–2243. [DOI] [PubMed] [Google Scholar]
- 46.Wesson J, Clemson L, Brodaty H, et al. A feasibility study and pilot randomised trial of a tailored prevention program to reduce falls in older people with mild dementia. BMC Geriatr September 2013; 13: 89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Burton E, Cavalheri V, Adams R, et al. Effectiveness of exercise programs to reduce falls in older people with dementia living in the community: A systematic review and meta-analysis. Clin Interv Aging February 2015; 10 421–434. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Peek K, Bryant J, Carey M, et al. Reducing falls among people living with dementia: A systematic review. Dementia (London) July 2020; 19(5): 1621–1640. [DOI] [PubMed] [Google Scholar]
- 49.Smith TO, Gilbert AW, Sreekanta A, et al. Enhanced rehabilitation and care models for adults with dementia following hip fracture surgery. Cochrane Database Syst Rev February 2020; (2): CD010569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Langhammer B, Bergland A, and Rydwik E. The importance of physical activity exercise among older people. Biomed Res Int December 2018; 1–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Taylor D. Physical activity is medicine for older adults. Postgraduate Med J January 2014; 90(1059): 26–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.American College of Sports Medicine, Chodzko-Zajko WJ, Proctor DN, et al. American College of Sports Medicine position stand: Exercise and physical activity for older adults. Med Sci Sports Exerc July 2009; 41(7): 1510–1530. [DOI] [PubMed] [Google Scholar]
- 53.Jia R-X, Liang J-H, Xu Y, et al. Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease: A meta-analysis. BMC Geriatr July 2019; 19: 181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Farina N, Rusted J, and Tabet N. The Effect of exercise interventions on cognitive outcome in Alzheimer’s disease: A systematic review. Int Psychogeriatr January 2014; 26(1): 9–18. [DOI] [PubMed] [Google Scholar]
- 55.Tolppanen A-M, Solomon A, Kulmala J, et al. Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia. Alzheimers Dement April 2015; 11(4): 434–443. e6. [DOI] [PubMed] [Google Scholar]
- 56.Najar J, Östling S, Gudmundsson P, et al. Cognitive and physical activity and dementia: A 44-year longitudinal population study of women. Neurology March 2019; 92(12): e1322–e1330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Krell-Roesch J, Feder NT, Roberts RO, et al. Leisure-time physical activity and the risk of incident dementia: The Mayo Clinic Study of Aging. J Alzheimers Dis, 2018; 63(1): 149–155. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Lamb SE, Sheehan B, Atherton N, et al. Dementia and physical, activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: Randomised controlled trial. BMJ May 2018; 361: k1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Forbes D, Thiessen EJ, Blake CM, et al. Exercise programs for people with dementia. Cochrane Database Syst Rev December 2013; (12): CD006489. [DOI] [PubMed] [Google Scholar]
- 60.Sparks LM. Exercise training response heterogeneity: Physiological and molecular insights. Diabetologia December 2017; (12): 2329–2336. [DOI] [PubMed] [Google Scholar]
- 61.Bouchard C, An P, Rice T, et al. Familial aggregation of VO(2max) response to exercise training: Results from the HERITAGE Family Study. J Appl Physiol September 1999; 87(3): 1003–1008. [DOI] [PubMed] [Google Scholar]
- 62.Montero D and Lundby C. Refuting the myth of non-response to exercise training: “Non-responders” do respond to higher dose of training. J Physiol June 2017; 595(11): 3377–3387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Brigadski T and Leßmann V. BDNF: A regulator of learning and memory processes with clinical potential. e-Neuroforum March 2014; 5(1): 1–11. [Google Scholar]
- 64.Mahalakshmi B, Maurya N, Lee S-D, et al. Possible neuroprotective mechanisms of physical exercise in neurodegeneration. Int J Mol Sci August 2020; 21(16): 1–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Stillman CM, Cohen J, Lehman ME, et al. Mediators of physical activity on neurocognitive function: A review at multiple levels of analysis. Front Hum Neurosci December 2016; 10: 626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Marinus N, Hansen D, Feys P, et al. The impact of different types of exercise training on peripheral blood brain-derived neurotrophic factor concentrations in older adults: A meta-analysis. Sports Med October 2019; 49(10): 1529–1546. [DOI] [PubMed] [Google Scholar]
- 67.Rojas Vega S, Strüder HK, Vera Wahrmann B, et al. Acute BDNF and cortisol response to low intensity exercise and following ramp incremental exercise to exhaustion in humans. Brain Res November 2006; 1121(1): 59–65. [DOI] [PubMed] [Google Scholar]
- 68.Ross LM, Porter RR, and Durstine JL. High-intensity interval training (HIIT) for patients with chronic diseases. J Sport Health Sci, 2016. June; 5(2): 139–144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Calverley TA, Ogoh S, Marley CJ, et al. HIITing the brain with exercise: Mechanisms, consequences and practical recommendations. J Physiol July 2020; 598(13): 2513–2530. [DOI] [PubMed] [Google Scholar]
- 70.Müllers P, Taubert M, and Müller NG. Physical exercise as personalized medicine for dementia prevention? Front Physiol May 2019; 10: 672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Andrieu S, Guyonnet S, Coley N, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): A randomised, placebo-controlled trial. Lancet Neurol May 2017; 16(5): 377–389. [DOI] [PubMed] [Google Scholar]
- 72.Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): A cluster-randomised controlled trial. Lancet August 2016; 388(10046): 797–805. [DOI] [PubMed] [Google Scholar]
- 73.Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, CT, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet, 2015. June 6; 385(9984): 2255–2263. [DOI] [PubMed] [Google Scholar]
- 74.Clare L and Woods RT. Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer’s disease: A review. Neuropsychol Rehabil September 2004; 14(4): 385–401. [Google Scholar]
- 75.Carrion C, Folkvord F, Anastasiadou D, et al. Cognitive therapy for dementia patients: A systematic review. Dement Geriatr Cogn Disord September 2018; 46(1–2): 1–26. [DOI] [PubMed] [Google Scholar]
- 76.Huntley JD, Gould RL, Liu K, et al. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open April 2015; 5(4): e005247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev February 2012; (2): CD005562. [DOI] [PubMed] [Google Scholar]
- 78.Wang L-Y, Pei J, Zhan Y-J, et al. Overview of meta-Analyses of five nonpharmacological interventions for Alzheimer’s disease. Front Aging Neurosci November 2020; 12: 594432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Rabipour S and Raz A. Training the brain: Fact and fad in cognitive and behavioral remediation. Brain Cogn July 2012; 79(2): 159–179. [DOI] [PubMed] [Google Scholar]
- 80.Valenzuela MJ, Matthews FE, Brayne C, et al. Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry May 2012; 71(9): 783–791. [DOI] [PubMed] [Google Scholar]
- 81.Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev March 2019; (3): CD013069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Edwards JD, Fausto BA, Tetlow AM, et al. Systematic review and meta-analyses of useful field of view cognitive training. Neurosci Biobehav Rev January 2018; 84 72–91. [DOI] [PubMed] [Google Scholar]
- 83.Hill NTM, Mowszowski L, Naismith SL, et al. Computerized cognitive training in older adults with mild cognitive impairment or dementia: A systematic review and meta-analysis. Am J Psychiatry April 2017; 174(4): 329–340. [DOI] [PubMed] [Google Scholar]
- 84.Lampit A, Hallock H, and Valenzuela M. Computerized cognitive training in cognitively healthy older adults: A systematic review and meta-analysis of effect modifiers. PLoS Med November 2014; 11(11): e1001756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology January 2018; 90(3): 126–135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Orgeta V, McDonald KR, Poliakoff E, et al. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev February 2020; (2): CD011961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Wilson BA. Towards a comprehensive model of cognitive rehabilitation. Neuropsychol Rehabil March 2002; 12(2): 97–110. [Google Scholar]
- 88.Clare L. Rehabilitation for people living with dementia: A practical framework of positive support. PLoS Med March 2017; 14(3): e1002245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Clare L, Kudlicka A, Oyebode JR, et al. Individual goal-oriented cognitive rehabilitation to improve everyday functioning for people with early-stage dementia: A multicentre randomised controlled trial (the GREAT trial). Int J Geriatr Psychiatry May 2019; 34(5): 709–721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Cerejeira J, Lagarto L, and Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol, 2012; 3: 73. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Hessler JB, Schäufele M, Hendlmeier I, et al. Behavioural and psychological symptoms in general hospital persons with dementia, distress for nursing staff and complications in care: Results of the General Hospital Study. Epidemiol Psychiatr Sci June 2018; 27(3): 278–287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Borsje P, Wetzels RB, Lucassen PL, et al. The course of neuropsychiatric symptoms in community-dwelling persons with dementia: A systematic review. Int Psychogeriatr March 2015; 27(3): 385–405. [DOI] [PubMed] [Google Scholar]
- 93.Mukherjee A, Biswas A, Roy A, et al. Behavioural and psychological symptoms of dementia: Correlates and impact on caregiver distress. Dement Geriatr Cogn Dis Extra December 2017; 7(3): 354–365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Hallikainen I, Hongisto K, Välimäki T, et al. The progression of neuropsychiatric symptoms in Alzheimer’s disease during a five-year follow-up: Kuopio ALSOVA study. J Alzheimers Dis January 2018; 61(4): 1367–1376. [DOI] [PubMed] [Google Scholar]
- 95.Alves GS, Carvalho AF, de Amorim de Carvalho L, et al. Neuroimaging findings related to behavioral disturbances in Alzheimer’s disease: A systematic review. Curr Alzheimer Res, 2017; 14(1): 61–75. [DOI] [PubMed] [Google Scholar]
- 96. 96. Kolanowski A, Boltz M, Galik E, et al. Determinants of behavioral and psychological symptoms of dementia: A scoping review of the evidence. Nurs Outlook October 2017; 65(5): 515–529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. 97. Cloak N and Al Khalili Y. Behavioral and psychological symptoms in dementia. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2021 [PubMed] [Google Scholar]
- 98. 98. van Dalen-Kok AH, Pieper MJC, de Waal MWM, et al. Association between pain, neuropsychiatric symptoms, and physical function in dementia: A systematic review and meta-analysis. BMC Geriatr April 2015;15: 49. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. 99. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology December 1994; 44(12): 2308–2314. [DOI] [PubMed] [Google Scholar]
- 100.Conn D and Thorpe L. Assessment of behavioural and psychological symptoms associated with dementia. Can J Neurol Sci March 2007; 34 Suppl 1: S67–S71. [DOI] [PubMed] [Google Scholar]
- 101.Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of nonpharmacological interventions to treat behavioural disturbances in older persons with dementia. The SENATOR-OnTop series. BMJ Open March 2017; 7(3): e012759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Seitz DP, Brisbin S, Herrmann N, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: A systematic review. J Am Med Dir Assoc July 2012; 13(6): 503–506. e2. [DOI] [PubMed] [Google Scholar]
- 103.Kales HC, Gitlin LN, and Lyketsos CG. Detroit expert panel on assessment and management of neuropsychiatric symptoms of dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J Am Geriatr Soc April 2014; 62(4): 762–769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.van der Steen JT, Smaling HJ, van der Wouden JC, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev July 2018; (7): CD003477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105.Margenfeld F, Klocke C, and Joos S. Manual massage for persons living with dementia: A systematic review and meta-analysis. Int J Nurs Stud August 2019; 96 132–142. [DOI] [PubMed] [Google Scholar]
- 106.Wu J, Wang Y, and Wang Z. The Effectiveness of massage and touch on behavioural and psychological symptoms of dementia: A quantitative systematic review and meta-analysis. J Adv Nurs October 2017; 73(10): 2283–2295. [DOI] [PubMed] [Google Scholar]
- 107.Ball EL, Owen-Booth B, Gray A, et al. Aromatherapy for dementia. Cochrane Database Syst Rev August 2020; (8): CD003150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Forbes D, Blake CM, Thiessen EJ, et al. Light therapy for improving cognition, activities of daily living, sleep, challenging behaviour, and psychiatric disturbances in dementia. Cochrane Database Syst Rev February 2014; (2): CD003946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Neal M and Barton Wright P. Validation therapy for dementia. Cochrane Database Syst Rev March 2003; (3): CD001394. [DOI] [PubMed] [Google Scholar]
- 110.Woods B, O’Philbin L, Farrell EM, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev March; (3): CD001120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Cohen-Mansfield J, Thein K, and Marx MS. Predictors of the impact of nonpharmacologic interventions for agitation in nursing home residents with advanced dementia. J Clin Psychiatry July 2014; 75(7): e666–e671. [DOI] [PubMed] [Google Scholar]
- 112.Scales K, Zimmerman S, and Miller SJ. Evidence-based nonpharmacological practices to address behavioral and psychological symptoms of dementia. Gerontologist January 2018; 58(suppl 1): S88–S102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Orgeta V, Qazi A, Spector AE, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev January January; (1): CD009125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Cheston R and Ivanecka A. Individual and group psychotherapy with people diagnosed with dementia: A systematic review of the literature. Int J Geriatr Psychiatry January 2017; 32(1): 3–31. [DOI] [PubMed] [Google Scholar]
- 115.Farina N, Morrell L, and Banerjee S. What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry January 2017; 32(1): 32–49. [DOI] [PubMed] [Google Scholar]
- 116.Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of Citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA February 2014; 311(7): 682–691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.McCleery J, Cohen DA, and Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev November November; (11): CD009178. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Nardell M and Tampi RR. Pharmacological treatments for frontotemporal dementias: A systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen March 2014; 29(2): 123–132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Scoralick FM, Louzada LL, Quintas JL, et al. Mirtazapine does not improve sleep disorders in Alzheimer’s disease: Results from a double-blind, placebo-controlled pilot study. Psychogeriatrics March 2017; 17(2): 89–96. [DOI] [PubMed] [Google Scholar]
- 120.Tampi RR, Tampi DJ, Balachandran S, et al. Antipsychotic use in dementia: A systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis September 2016; 7(5): 229–245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Kales HC, Gitlin LN, and Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ March 2015; 350: h369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev March March; (3): CD007726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Bessey LJ and Walaszek A. Management of behavioral and psychological symptoms of dementia. Curr Psychiatry Rep July 2019; 21(8): 66. [DOI] [PubMed] [Google Scholar]
- 124.Bozymski KM, Lowe DK, Pasternak KM, et al. Pimavanserin: A novel antipsychotic for Parkinson’s disease psychosis. Ann Pharmacother June 2017; 51(6): 479–487. [DOI] [PubMed] [Google Scholar]
- 125.Ballard C, Banister C, Khan Z, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: A phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol March 2018; 17(3): 213–222. [DOI] [PubMed] [Google Scholar]
- 126.Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer’s dementia: Two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry April 2020; 28(4): 383–400. [DOI] [PubMed] [Google Scholar]
- 127.Davies SJ, Burhan AM, Kim D, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol May 2018; 32(5): 509–523. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.St Louis EK and Boeve BF. REM sleep behavior disorder: Diagnosis, clinical implications, and future directions. Mayo Clin Proc November 2017; 92(11): 1723–1736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Na HR and Cho ST. Relationship between Lower Urinary Tract Dysfunction and Dementia. Dement Neurocogn Disord September 2020; 19(3): 77–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Tornic J and Panicker JN. The management of lower urinary tract sdysfunction in multiple clerosis. Curr Neurol Neurosci Rep June 2018; 18(8): 54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Panicker JN, Fowler CJ, and Kessler TM. Lower urinary tract dysfunction in the neurological patient: Clinical assessment and management. Lancet Neurol July 2015; 14(7): 720–732. [DOI] [PubMed] [Google Scholar]
- 132.Ransmayr GN, Holliger S, Schletterer K, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology January 2008; 70(4): 299–303. [DOI] [PubMed] [Google Scholar]
- 133.Averbeck MA, Altaweel W, Manu-Marin A, et al. Management of LUTS in persons with dementia and associated disorders. Neurourol Urodyn February 2017; 36(2): 245–252. [DOI] [PubMed] [Google Scholar]
- 134.Eustice S, Roe B, and Paterson J. Prompted voiding for the management of urinary incontinence in adults. Cochrane Database Syst Rev February February; (2): CD002113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Jirovec MM and Templin T. Predicting success using individualized scheduled toileting for memory-impaired elders at home. Res Nurs Health February 2001; 24(1): 1–8. [DOI] [PubMed] [Google Scholar]
- 136.Amaro JL, Gameiro MO, and Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. Int Urogynecol J Pelvic Floor Dysfunct October 2005; 16(5): 355–358. [DOI] [PubMed] [Google Scholar]
- 137.Lee BA, Kim SJ, Choi DK, et al. Effects of pelvic floor muscle exercise on urinary incontinence in elderly women with cognitive impairment. Int Neurourol J December 2017; 21(4): 295–301. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Herderschee R, Hay-Smith ECJ, Herbison GP, et al. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women: Shortened version of a cochrane systematic review. Neurourol Urodyn April 2013; (4): 325–329. [DOI] [PubMed] [Google Scholar]
- 139.Panicker JN and Fowler CJ. The bare essentials: Uro-neurology. Pract Neurol June 2010; 10(3): 178–185. [DOI] [PubMed] [Google Scholar]
- 140.Warren K, Burden H, and Abrams P. Mirabegron in overactive bladder patients: Efficacy review and update on drug safety. Ther Adv Drug Saf October 2016; 7(5): 204–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr March 2020; 20(1): 109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.De Giorgi R and Series H. Treatment of inappropriate sexual behavior in dementia. Curr Treat Options Neurol September 2016; 18(9): 41. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 143.Chapman KR, Tremont G, Malloy P, et al. The role of sexual disinhibition to predict caregiver burden and desire to institutionalize among family dementia caregivers. J Geriatr Psychiatry Neurol January 2020; 33(1): 42–51. [DOI] [PubMed] [Google Scholar]
- 144.de Medeiros K, Rosenberg PB, Baker AS, et al. Improper sexual behaviors in elders with dementia living in residential care. Dement Geriatr Cogn Disord October 2008; 26(4): 370–377. [DOI] [PubMed] [Google Scholar]
- 145.Alagiakrishnan K, Lim D, Brahim A, et al. Sexually inappropriate behaviour in demented elderly people. Postgrad Med J July 2005; 81(957): 463–466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146.Ahmed RM, Kaizik C, Irish M, et al. Characterizing sexual behavior in frontotemporal dementia. J Alzheimers Dis March 2015; 46(3): 677–686. [DOI] [PubMed] [Google Scholar]
- 147.Joller P, Gupta N, Seitz DP, et al. Approach to inappropriate sexual behaviour in people with dementia. Can Fam Physician March 2013; 59(3): 255–260. [PMC free article] [PubMed] [Google Scholar]
- 148.Marshall GA, Amariglio RE, Sperling RA, et al. Activities of daily living: Where do they fit in the diagnosis of Alzheimer’s disease? Neurodegener Dis Manag October 2012; 2(5): 483–491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 149.Liu-Seifert H, Siemers E, Selzler K, et al. Correlation between cognition and function across the spectrum of Alzheimer’s disease. J Prev Alzheimers Dis, 2016; 3(3): 138–144. [DOI] [PubMed] [Google Scholar]
- 150.Boyle PA, Malloy PF, Salloway S, et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry April 2003; 11(2): 214–221. [PubMed] [Google Scholar]
- 151.Steultjens EMJ, Dekker J, Bouter LM, et al. Evidence of the efficacy of occupational therapy in different conditions: An overview of systematic reviews. Clin Rehabil May 2005; 19(3): 247–254. [DOI] [PubMed] [Google Scholar]
- 152.Voigt-Radloff S, Graff M, Leonhart R, et al. A multicentre RCT on community occupational therapy in Alzheimer’s disease: 10 sessions are not better than one consultation. BMJ Open August 2011; 1(1): e000096. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Bennett S, Laver K, Voigt-Radloff S, et al. Occupational therapy for people with dementia and their family carers provided at home: A systematic review and meta-analysis. BMJ Open November 2019; 9(11): e026308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 154.Letts L, Edwards M, Berenyi J, et al. Using occupations to improve quality of life, health and wellness, and client and caregiver satisfaction for people with Alzheimer’s disease and related dementias. Am J Occup Ther October 2011; 65(5): 497–504. [DOI] [PubMed] [Google Scholar]
- 155.Daly Lynn J, Rondón-Sulbarán J, Quinn E, et al. A systematic review of electronic assistive technology within supporting living environments for people with dementia. Dementia (London) November 2019; 18(7–8): 2371–2435. [DOI] [PubMed] [Google Scholar]
- 156.Hunter SW, Divine A, Omana H, et al. Effect of learning to use a mobility aid on gait and cognitive demands in people with mild to moderate Alzheimer’s disease: Part I. Cane. J Alzheimers Dis, 2019; 71(s1): S105–S114. [DOI] [PubMed] [Google Scholar]
- 157.Hunter SW, Divine A, Omana H, et al. Effect of learning to use a mobility aid on gait and cognitive demands in people with mild to moderate Alzheimer’s disease: Part II. 4-Wheeled Walker. J Alzheimers Dis, 2019; 71(s1): S115–S124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.King AC and Dwan C. Electronic memory aids for people with dementia experiencing prospective memory loss: A review of empirical studies. Dementia (London) August 2019; 18(6): 1994–2007. [DOI] [PubMed] [Google Scholar]
- 159.McKinstry B and Sheikh A. The use of global positioning systems in promoting safer walking for people with dementia. J Telemed Telecare July 2013; (5): 288–292. [DOI] [PubMed] [Google Scholar]
- 160.Nijhof N, Hoof J van, Gemert-Pijnen JEWC van, et al. The behavioral outcomes of a technology-supported leisure activity in people with dementia. Technol Disabil April 2013; 25(4): 263–273. [Google Scholar]
- 161.Ienca M, Fabrice J, Elger B, et al. Intelligent assistive technology for Alzheimer’s disease and other dementias: A systematic review. J Alzheimers Dis February 2017; 56(4): 1301–1340. [DOI] [PubMed] [Google Scholar]